American researchers have discovered specific patterns of symptoms that make it possible to diagnose patients with ...

Brent Beasley, MD, a former internal medicine physician and geriatrician who was diagnosed with early-onset Alzheimer's ...

Blinded safety data from the ongoing Phase 2 trial suggest no treatment-related amyloid-related imaging abnormalities (ARIA) with PRI-002 Drug ...

A key Alzheimer’s drug has finally revealed its secret. Researchers discovered that lecanemab works by activating the brain’s immune cells—but only through a specific part of the antibody called the ...

Research roundtable highlights early detection, biomarkers, interventions ...

The Alzheimer's Drug Discovery Foundation (ADDF) today announced the launch of the third phase of its Diagnostics Accelerator (DxA), backed by an additional $50 million in funding, bringing the ...

New data show that blarcamesine completely rescued impaired motor function Biomarker of nerve fiber density of dopaminergic nerve cells indicating fiber regrowth in striatum with blarcamesine New ...

Gov. Tate Reeves has signed a bill requiring state-regulated health insurance plans in Mississippi to cover biomarker testing ...

A recent study shows that combining magnetic brain scans with computer models can safely measure how dementia medications ...

A research team from the Department of Pharmacology and Pharmacy, LKS Faculty of Medicine of the University of Hong Kong ...

GOTHENBURG, SE / ACCESS Newswire / March 17, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that i ...

Cognition Therapeutics, Inc., (the 'Company” or 'Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented an analysis from the Phase 2 ...